Market Newsdesk

Investors with losses are encouraged to contact the firm before November 20, 2020; click


here


to submit trade information

LOS ANGELES, Nov. 13, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of GoHealth, Inc. (NASDAQ: GOCO) investors that acquired shares in connection with GoHealth’s July 2020 initial public offering. Investors have until November 20, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

On July 15, 2019, GoHealth sold approximately 43.5 million shares of stock in its initial public stock offering (the “IPO”), at $21.00 per share raising almost $914 million in new capital.

On August 19, 2020, in GoHealth’s first quarterly earnings report following the IPO, announced that it had incurred a net loss of $22.9 million in its 2nd Quarter after reporting net income of $15.3 million in the prior-year period.

Shares of GoHealth’s stock are presently trading at almost 50% below its recent IPO price, at $14.26 per share.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

BRENTWOOD, Tenn, Nov. 13, 2020 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments without the use of surgery or opioids, today announces that management will participate in the Virtual Fall Investor Summit November 16-18, 2020.

Jeff Ervin, IMAC’s CEO, will kick off the Healthcare Track with his presentation at 9:00AM ET on November 16, 2020. For those attending the conference, his presentation can be accessed at 855-229-8310.

Mr. Ervin will also be available for one-on-one investor meetings. Those interested in scheduling a meeting with management should contact the Fall Investor Summit organizers at https://investorsummitgroup.com.

About IMAC Holdings, Inc.

IMAC Holdings was created in March 2015 to expand on the footprint of the original IMAC Regeneration Center, which opened in Kentucky in August 2000. IMAC Regeneration Centers combine life science advancements with traditional medical care for movement restricting diseases and conditions. IMAC owns or manages 15 outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies. It has partnered with several active and former professional athletes, opening six Ozzie Smith IMAC Regeneration Centers, two David Price IMAC Regeneration Centers, as well as Mike Ditka IMAC Regeneration Centers and a Tony Delk IMAC Regeneration Center. IMAC’s outpatient medical clinics emphasize its focus around treating sports and orthopedic injuries and movement-restricting diseases without surgery or opioids. More information about IMAC Holdings, Inc. is available at www.imacregeneration.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as “anticipate,” “expect,” “believe,” “may,” “will,” “should” or other comparable terms, are based largely on IMAC’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers’ requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe
[email protected]

Investor Relations:
Bret Shapiro
(516) 222-2560
[email protected]

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD.

The BioPub webcast will be held Friday, November 13, 2020 at noon EST. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.

BioPub
 has been analyzing small-cap special situation biotech investments for 7 years to readers in over 40 countries.

BioPub.co Presents: Catching up with Algernon
Nov 13, 2020 12:00 PM EST

Please click the link below to join the webinar:
https://us02web.zoom.us/j/86387749592

Or iPhone one-tap : 
    US: +16465588656, 86387749592#  or +16699009128, 86387749592# 
Or Telephone:
    Dial (for higher quality, dial a number based on your current location):
        US: +1 646 558 8656  or +1 669 900 9128  or +1 253 215 8782  or +1 301 715 8592  or +1 312 626 6799  or +1 346 248 7799 

Webinar ID: 863 8774 9592

International numbers available: https://us02web.zoom.us/u/kdHPNqmy0h

About

 


BioPub

BioPub.co
 is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don’t get and presence at meetings others don’t bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701

[email protected]

[email protected]

www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release


.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 4:00 p.m. ET.

A live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.

RAPT
Media Contact:

Angela Bitting
[email protected]
(925) 202-6211

RAPT
Investor Contact:

Sylvia Wheeler
[email protected]

– Data show longer-term, differentiated safety profile
of
vebicorvir
and
the
importance of HBV
preg
e
n
o
mic
(
pg
) RNA as a key biomarker
,
as well as
highlight Assembly Bio’s core inhibitor
clinical
pipeline
–

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that data from its HBV core inhibitor programs and related research will be highlighted during four poster sessions – including two late-breakers – at the 2020 American Association for the Study of Liver Diseases (AASLD) The Liver MeetingDigital Experience^TM. The posters include data from the company’s HBV core inhibitor research and development programs, as well as a collaborative translational study using Assembly Bio’s sensitive HBV nucleic acid assays.

“Findings from these studies are adding to a growing body of clinical data that supports the differentiated safety profile of vebicorvir in combination with nucleos(t)ide therapy,” said Ira M. Jacobson, MD, Director of Hepatology at New York University Langone Medical Center. “New treatment options for HBV patients are long overdue and the addition of a core inhibitor to the standard-of-care regimen may offer better chronic suppressive therapy to a significant patient population. These longer-term safety data, along with the demonstrated association of HBV pgRNA and changes in HBV viral antigens presented at this conference, are very encouraging and support the continued advancement of the company’s core inhibitor programs.”  

“Chronic hepatitis B virus infection is incredibly complex. Through this research, we are proud to continue to contribute to the scientific community’s understanding of hepatitis B and the importance of deepening virologic suppression as it relates to both improving chronic suppressive therapy and reducing downstream clinically important liver-related events,” said John McHutchison, AO, MD, Chief Executive Officer and President at Assembly Biosciences. “Further, these data highlight the potential of our more potent core inhibitor candidates, ABI-H2158 and ABI-H3733. We believe that core inhibitors represent a significant advancement in the HBV field and we remain focused on upcoming milestones, including planned Phase 3 registrational trials of vebicorvir in China and globally in the first half of 2021.”   

The Liver Meeting Digital Experience 2020 Presentations:

The posters will be made available on the “Events and Presentations” page in the Investors section of assemblybio.com.

Vebicorvir (VBR,
or
ABI-H0731)
, Assembly Bio’s Lead HBV Core Inhibitor


Poster Presentation 820

:
Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor
VBR
in an open-label extension study

Presenter: Ira M. Jacobson, MD, Director, Hepatology, NYU Langone Health

This poster includes data from a controlled comparison of 24 patients receiving placebo + nucleos(t)ide analogs (NrtI) for 24 weeks versus 95 patients receiving Assembly Bio’s lead core inhibitor product VBR + NrtI for up to 1.5 years. Data support the differentiated safety profile and continued development of VBR combination therapy.

Key
R
esults:

• The safety profile of combination treatment with VBR+NrtI was similar to placebo+NrtI over a 24-week controlled-comparison and was stable with longer-term treatment of VBR+NrtI up to 1.5 years.
• Rashes without systemic involvement observed with VBR+NrtI treatment were predominantly Grade 1 resolving without VBR+NrtI interruption.
• There was no pattern of increased alamine aminotransferase (ALT) and/or aspartate aminotransferase (AST), indicative of hepatoxicity.

Late


–


Breaking


Poster


LP37


:

Changes in viral antigens are more strongly associated with HBV pgRNA than HBV DNA in studies of vebicorvir and NrtI in treatment-naive patients with chronic HBV infection

Presenter: Mark Sulkowski, MD, Medical Director, Viral Hepatitis Center, Johns Hopkins University School of Medicine

This poster details the results of post hoc analyses of data from studies of VBR in treatment naïve patients with HBeAg positive chronic HBV infection to better understand the correlations between changes in HBV DNA and pgRNA with those of other HBV antigens. Two approaches were used: correlation analyses with a Pearson’s coefficient and a Mixed-Effects Model for Repeated Measures. These results demonstrate the importance of pgRNA as a meaningful biomarker for chronic HBV.

Key
R
esults:

• Changes in other HBV antigens are more strongly associated with the change in pgRNA compared with the change in HBV DNA.
• Correlations between pgRNA and HBeAg and HBcrAg were greater relative to the correlations with HBsAg, likely due to the substantial contribution of HBV integrants to HBsAg levels.
• A >2 log₁₀ decline in pgRNA in patients receiving VBR + entecavir (ETV) more significantly predicted the decline in the HBeAg and HBcrAg consistent with the second phase decline with core inhibitor treatment reflecting reduction in cccDNA pools.

Assembly Bio’s
Next-Generation of
Core Inhibitors


Late


–


Breaking


Poster


LP45

:
Amino acid substitutions in the inhibitor binding pocket of HBV core protein confer differential changes in susceptibility to three generations of HBV core inhibitors

Presenter: Dawei Cai, PhD, Senior Scientist, Assembly Bio

This poster describes the in vitro resistance profiles of Assembly Bio’s first-generation core inhibitor, VBR, and next-generation core inhibitor candidates ABI-H2158 (2158) and ABI-H3733 (3733). Researchers evaluated the antiviral activity of these candidates against known substitutions to the core inhibitor binding pocket. They also assessed whether these substitutions affect the ability of core inhibitors to block cccDNA formation as well as HBV replication through inhibition of pgRNA encapsidation.

Key
Results:

• 2158 and 3733 showed greater potency in terms of preventing cccDNA formation compared with VBR and had more favorable resistance profiles against a panel of substitutions.
• ETV retains activity against all tested core protein substitutions suggesting that combination therapy with NrtIs will prevent viral breakthrough due to pre-existence or potential emergence of core protein substitutions, consistent with the current clinical data.

Use of
Assembly Bio’s Highly Sensitive HBV Assays
to Characterize
the
A
ssociation of HBV with HCC


Poster 738

:
Persistently detectable serum HBV pgRNA is associated with subsequent HCC development in chronic hepatitis B patients receiving chronic NrtI treatment

Presenter:
 Lung-Yi Mak, MBBS, MRCP, PDipID, FHKCP, FHKAM Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong

In this poster, researchers detail findings from a case control study to assess whether residual HBV viraemia is associated with the development of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The study evaluated 104 chronic HBV patients, 39% of whom had cirrhosis, on ≥ 3 years ETV with unquantifiable HBV DNA by standard assays. Findings highlight the need for more potent viral suppression to further reduce the risk of HCC.

Key
Results:

• More sensitive assays revealed that patients still had ongoing replication as evidenced by detection of HBV DNA and pgRNA.
• More than 50% of chronic HBV patients on ETV with HBV DNA<LLOQ (lower limit of quantification) by standard assay had persistent viraemia as determined by a more sensitive HBV DNA assay.
• Detectable viral nucleic acids (HBV DNA and/or pgRNA) were associated with a higher 2-year risk of HCC development.

About HBV

Chronic hepatitis B virus (HBV) infection is a debilitating disease of the liver that afflicts over 250 million people worldwide with up to 90 million people in China, as estimated by the World Health Organization. HBV is a global epidemic that affects more people than hepatitis C virus (HCV) and HIV infection combined—with a higher morbidity and mortality rate. HBV is a leading cause of chronic liver disease and need for liver transplantation, and up to one million people worldwide die every year from HBV-related causes.

The current standard of care for patients with chronic HBV infection is life-long suppressive treatment with medications that reduce, but do not eliminate, the virus, resulting in very low cure rates. There is a significant unmet need for new therapies to treat HBV.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to improve the treatment options available to chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Forward-Looking Statements

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to initiate and complete clinical trials involving its HBV therapeutic product candidates in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; Assembly Bio may not observe sustained virologic response in patients who stop therapy in Study 211; Assembly Bio’s ability to maintain financial resources necessary to continue its clinical trials and fund business operations; any impact that the spread of the coronavirus and resulting COVID-19 pandemic may have on Assembly Bio’s business and operations, including initiation and continuation of its clinical trials or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor
Contact

Assembly Biosciences, Inc.
Lauren Glaser
Senior Vice President, Investor Relations and Corporate Affairs
(415) 521-3828
[email protected]

Media Contact

Sam Brown Inc.
Audra Friis
(917) 519-9577
[email protected]

MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided additional information about its upcoming virtual 2020 Annual Meeting of Shareholders (“Annual Meeting”). Timothy R. Wright, Chief Executive Officer, is scheduled to present an overview of the Company, and Rohit Kashyap, Ph.D., Executive Vice President and Chief Commercial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, are scheduled to present an overview of the Company’s commercial and R&D initiatives. Additional members of senior management also plan to be available for a question and answer session from shareholders as of the record date of 5:00 p.m. Eastern Time on October 7, 2020. Guests may join the virtual 2020 Annual Meeting, including the shareholder question and answer session, in a listen-only mode without a control number.

The meeting is scheduled to be held on Friday, November 20, 2020 at 10:00 a.m. Eastern Time and will be conducted in a virtual format only in light of public health concerns regarding the coronavirus (COVID-19) outbreak.

To participate in the virtual Annual Meeting, shareholders must visit www.virtualshareholdermeeting.com/MDXG2020 on Friday, November 20, 2020 and enter the 16-digit control number found on their proxy materials or voting instruction form. Please log in at least 15 minutes before the Annual Meeting begins to ensure ample time to complete the check-in procedures and test your computer audio system. Presentation materials will be posted on the Webcasts & Presentations section of the Company’s website immediately prior to the start of the meeting.

The Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) and has mailed it with an accompanying proxy card for the virtual 2020 Annual Meeting to its shareholders. A free copy of the Proxy Statement and other relevant documents that the Company files with the SEC may be obtained through the SEC’s website at www.sec.gov or on the Company’s website at www.mimedx.com.

About
MiMedx

MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contact

Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
[email protected]

 

NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) — via InvestorWire — Exchange Listing, LLC and its chairman, Peter Goldstein, will be joined by Erik Sloane, chief revenue officer of NEO, on Monday, Nov. 16, to celebrate Exchange Listing’s acceptance into NEO’s Trusted Service Provider Program.

The NEO Exchange is Canada’s next-generation senior stock exchange, bringing much-needed competition and disruption to the Canadian market. Focused on doing what is right for investors and capital-raising companies, NEO offers a Trusted Service Provider Program, which enables a better public listing experience for issuers.

Members of the NEO Exchange Trusted Service Provider Program are leading experts in their fields, across all verticals, who are carefully vetted; committed to meeting the needs of capital-raising companies; and aligned with NEO’s vision, values and commitment to exceptional client service.

Exchange Listing LLC was founded to provide growth companies with a cost-effective one-stop strategic planning and implementation service to list on senior exchanges.

“We are currently working with two issuer clients on their application processes to list to the NEO Exchange,” Goldstein said. “One issuer is a European specialty pharmaceutical company and the other is a U.S.-based global provider of award-winning e-commerce and fintech solutions. Both companies are looking to benefit from the NEO platform technology for trading, to broaden investor confidence, to improve liquidity and to gain global exposure.”

About NEO Exchange

NEO Exchange is a progressive stock exchange that brings together investors and capital raisers within a fair, efficient and service-oriented environment. Fully operational since June 2015, NEO puts investors first and provides access to trading all Canadian-listed securities on a level playing field. The NEO Exchange lists senior companies and investment products seeking a stock exchange that enables investor trust, quality liquidity and broad awareness, including unfettered access to market data.

Connect with NEO: Website | LinkedIn | Twitter 

About Exchange Listing LLC

The objective to list on a publicly traded exchange has become increasingly complex. Exchange Listing was launched to provide a myriad of services, including capital markets advisory services to private companies looking to access the public capital markets as well as public companies looking to grow to the next level. Our role is to actively work hand in hand with our clients, senior exchanges, investment bankers, lawyers, auditors, etc., and to add shareholder value with a focus on structure, timing, managing the exchange listing application process and to make introductions to outside resources, as needed. For more information, please visit: http://exchangelistingllc.com or contact [email protected].

Wire Service Contact

InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
[email protected]

SPRINGFIELD, Nov. 13, 2020 (GLOBE NEWSWIRE) — Cardinal Renewables, a strategic partnership between the global investment firm, The Carlyle Group, and Alchemy Renewable Energy, an industry leader in renewable energy projects and tax equity financing, has secured a power purchase agreement (PPA) with Direct Energy Business, one of North America’s largest retail providers of electricity, natural gas, and home business energy-related services, through Twittys Creek Solar, LLC, supporting construction of its a 14 MW_AC solar power installation located in Charlotte County, Virginia.

Providing a lasting clean energy alternative to traditional fossil fuels, Twittys Creek reduces the amount of harmful carbon emissions released into the atmosphere. The new solar installation, developed by Holocene Clean Energy, is expected to be operational in December 2020.

“We are excited to expand our operations with Twittys Creek, allowing us to broaden our coverage into Virginia and launching us one step closer to the clean energy transition,” said Lacie Clark, CEO of Alchemy Renewable Energy. “The project would not have been possible without our joint venture with Carlyle, and collaboration with Direct Energy Business and Holocene Clean Energy.”

The new installation spans approximately 75-acres and will generate nearly 14 MW_AC of clean power, which is estimated to offset over 700,000 Mt CO2e over 40 years of operation. This emissions reduction is equivalent to powering about 2,250 homes, removing nearly 4,125 passenger cars from the road, or reducing gasoline consumption by 2.1 million gallons every year the project generates electricity. By adding a new, renewable energy generation source to the grid, Twittys Creek Solar, LLC, fosters a cleaner future for power supply.

“Each of our renewable energy projects creates new power generation assets for the United States,” said Pooja Goyal, Co-Head of the Infrastructure Group at The Carlyle Group. “Twittys Creek Solar, LLC, is expected to have a positive impact on the community of Charlotte County and the region by providing a clean energy source that is intended to provide efficient power delivery, improve the environment, and reduce dependency on fossil fuels.”

“We appreciate our collaboration with Cardinal Renewables and Direct Energy Business, who ultimately helped give life to the project. After working so closely with our partners and Charlotte County, seeing the stakes put into the ground was a truly joyful moment for our team,” said Laura Tillett, Business Development at Holocene Clean Energy.

“Direct Energy is proud to have partnered with Holocene and Cardinal Renewables to commence construction on Twittys Creek. It is important for us to have sustainable assets as part of our supply portfolio to assist our customers in achieving their carbon reduction goals,” said Ray Polakowski, Manager of Wholesale Origination for Direct Energy Business. 

“Competitive markets drive cost-effective renewable energy adoption and create associated localized economic development benefits. This 14 MW_AC solar project located in Charlotte County, Virginia will benefit the community and consumers,” said Ron Cerniglia, Direct Energy’s Director of Corporate & Regulatory Affairs.  

 

About Cardinal Renewables

Cardinal Renewables, a strategic partnership between The Carlyle Group and Alchemy Renewable Energy, is focused on creating long-term value for investors, companies, and communities through the development, acquisition, financing, and operation of solar power generation projects throughout the United States, with a focus on projects ranging from 5-80 MW_AC. The Carlyle Group, through the Carlyle Renewable and Sustainable Energy Fund, has made a $100 million commitment to this partnership.

 

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $230 billion of assets under management as of September 30, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 1,800 people in 30 offices across six continents. Further information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.

 

About Alchemy Renewable Energy

Alchemy Renewable Energy is an industry leader in renewable energy projects as well as comprehensive long-term debt and tax equity financing. The firm utilizes a credentialed team, a strong network of joint ventures, and parent company Monarch Private Capital to support premium mid-size utility-scale renewable energy projects, including solar and biomass power generation. The Company leverages Monarch Private Capital’s tax equity placement services as the final element of its projects’ capital structure. In addition, Alchemy reduces overall project costs and produce higher overall investor returns by eliminating the need to source third-party development and financing support.

 

About Holocene Clean Energy

Holocene Clean Energy is building the foundation for the future of solar power supply, battery storage, and delivery. As a leading innovator, they create scalable distributed solar generation and storage project portfolios to reduce dependency on traditional fuels, increase grid reliability, and improve the efficiency of power delivery. The Company’s distributed generation strategy allows power consumers to procure renewable energy at competitive prices while providing meaningful benefits to local communities hosting their generation facilities.

 

About Direct Energy

Direct Energy is one of North America’s largest retail providers of electricity, natural gas, and home and business energy-related services with nearly four million customers. Direct Energy gives customers choice, simplicity, and innovation where energy, data, and technology meet. A subsidiary of Centrica plc (LSE: CNA), an international energy and services company, Direct Energy, its subsidiaries and/or affiliates, operate in 50 U.S. states plus the District of Columbia and 8 provinces in Canada. To learn more about Direct Energy, please visit www.directenergy.com.

Jane Rafeedie
Monarch Private Capital
4702838431
[email protected]

    V-Health Passport™

Test Agnostic & Secure Digital COVID Health Passport

to Get Sports Fans Back Into Stadiums 



Liverpool Legend Takes COVID 19 Orient Gene / Healgen

Rapid Antigen & Antibody Test 

To view the
video
click here

https://youtu.be/jF3iibf4dhY

MANCHESTER, United Kingdom, Nov. 13, 2020 (GLOBE NEWSWIRE) — One of the most iconic and celebrated figures in British football history Sir Kenny Dalglish MBE is the latest high-profile name from the world of sport to join British cyber technology company VST Enterprises (VSTE) as its Global Sporting Ambassador for football. The role is established through VSTE’s American partner company VR Sports Group, which is also giving VSTE a powerful presence in the USA with further intention of a global rollout of their cutting-edge platform V-Health Passport™.

The celebrated Scottish football player and former Liverpool Manager has joined forces with former England Rugby Captain and 2003 World Cup Winner Mike Tindall MBE, equestrian World Champion and Olympic Silver Medalist Zara Tindall MBE to pioneer a UK wide campaign to get sports fans back into stadiums.

The Manchester based cyber technology company which was founded by tech entrepreneur Louis-James Davis has developed a secure digital health passport – V-Health Passport™ as the key to unlocking the return of fans back to football stadiums. The TEST AGNOSTIC health passport app – which works alongside all Covid 19 testing kits including PCR lab tests and new emerging 15 minute rapid ‘antigen’ and 10 minute ‘antibody’ test kits – also has its own unique contact tracing technology which is specifically designed for sports and football stadiums, music and theatre venues.

As VSTE’s global football ambassador, Sir Kenny will highlight the importance of using the secure VCode^® digital technology behind V-Health Passport™ and the importance of using the ‘best in class’ technology alongside rapid Covid testing for sports fans and players. Sir Kenny will also raise the important issue of all football players being subject to rapid Covid testing, in addition to existing PCR based lab tests as an early warning indicator.

Sir Kenny undertook a Covid 19 rapid ‘antigen’ and rapid antibody test in Liverpool recently which was administered by CHB Medical. The nasal swab Orient Gene /Healgen rapid ‘antigen’ test was administered first taking 15 minutes, followed by the finger prick Orient Gene rapid ‘antibody’ test which also took ten minutes to administer. Both results showed Sir Kenny was negative on both tests and the results were then uploaded to his ‘test agnostic’ V-Health Passport™ in under 30 seconds.

Commenting on the Orient Gene/Healgen rapid ‘antigen’ and rapid ‘antibody’ tests Dr Robert Hutchins MB BS MS FRCS (Eng) FRCS (Gen Surg) a London NHS Consultant said;

“Rapid point of care Covid-19 testing is the most promising way to ensure a return to normal activity and an assurance that we capture infections and prevent further re
infection. Rapid ‘antigen’ testing on a regular basis, alongside rapid ‘antibody’ screening and then authenticated in a secure digital health passport technology such as VHealth Passport would give much greater mobility and confidence to the public.

In d
oing so it would allow the public to return to their workplace environments, airline passengers being ‘fit to fly’ and more confident with the health status of their fellow passengers. It would also allow sports to return safely and allow team selection with confidence. Fans would be able to potentially return to the stadiums having taken a test and uploaded their results into the secure VHealth Passport verifying their identity and test status.”

Sir Kenny, along with Mike Tindall MBE and Zara Tindall MBE will champion the Manchester cyber technology’s ‘FANS ARE BACK™’ pilot scheme for football fans which has been submitted to the UK Government, The Department For Digital, Culture, Media and Sport (DCMS), Sports Minister Nigel Huddlestone and the Sports Technology Innovation Group (STIG).

The ‘FANS ARE BACK™’ pilot is an end-to-end solution for sports fans with Covid rapid testing using 15minute rapid ‘antigen’ and 10 minute rapid ‘antibody’ test kits, a secure digital V-Health Passport™ and V-Health Passports ‘True Contact™’ contact tracing solution to get fans back into stadiums safely and watching their beloved teams. The technology can also be integrated with smart stadium devices for security gates and multi-functional safe zone cams for high flow body heat monitoring and social distancing crowd control.

The scheme was devised by VSTE and a consortium of British companies including leading public safety and event /venue management company Halo Solutions, occupational health company Latus Health, football and sports marketing/ rights agency holder REDSTRIKE. The pilot campaign has also been submitted to the Sports Ground Safety Authority (SGSA) and the Premier League. It has also received the backing and support of former Sports Minister Rt. Hon. Richard Caborn. Caborn was one of the longest serving Sports Ministers under Tony Blair and was responsible for successfully bringing the 2012 Olympics to London.

Commenting on his new appointment Sir Kenny Dalglish MBE said;

“
I was impressed to learn about what Louis-James and his team at
VST
Enterprises are trying to
achieve with their
‘

FANS ARE BACK


™’

campaign and the V-Health Passport
™
technology. Getting fans back into football stadiums safely is the number one priority for all football clubs across the UK and globally right now and for the future of the game.
Without the fans there is no beautiful game, it
’
s a way of life to so many people, it
’
s tribal, it’s about a group of like-minded people who have a passion and who are proud of what they’re team represents.

Football is part of our DNA, it
’
s our culture,
we have been through two world wars and many national tragedies along the way, but football has always been a unifying force. The Corona virus outbreak has impacted many people across the country, families have lost loved ones. I too myself tested positiv
e for
Covid
earlier this year and the support and care I received from the NHS was outstanding, so I understand firsthand. Football and sport in the UK contribute massively to positive mental health and any technology that can ensure that fans safely retur
n to the game is a winner.
”

Commenting on the appointment VSTE Founder & CEO Louis-James Davis said;

“
We are truly
honoured
and delighted to have such an iconic football player and manager as Sir Kenny joining us as a global sporting ambassador for
VST
Enterprises and the V-Health Passport
™
project. Sir Kenny
’
s achievements in football both as a player and manager are unsurpassed. But his relationship with the fans, in particular Liverpool FC is what makes him stand out as a truly iconic figure in foot
ball alongside the greats of the game like Bill Shankly, Bob Paisley, and Sir Matt Busby.
”

The VCode^® and VPlatform^® technology which powers the V-Health Passport™ has being hailed as the cyber security’s version of ‘human DNA’. The technology has a number of applications and uses from secure health passports to ticketing, payments, identity provisioning and authentication across all spectator sports. The technology’s innovative capabilities across football, rugby, golf and motorsport is vast. It can be used for secure paperless ticketing to stamping out counterfeit tickets, security and access, health passports for players and fans, content delivery and sponsor /brand activation.

The ultra secure V-Health Passport™ also uses the VCode^® security coding which has been referred to as the cyber world’s equivalent of human DNA. Bar codes and QR codes represent 1st and 2nd generation code scanning technology which is unsecure. QR codes in particular can be cloned and hacked under a process called “Attagging”. In India alone there are over 1 BILLION fraudulent financial transactions every day using QR codes. The use of any form of a QR code in a health passport could potentially lead to a persons data being hacked and compromised.

Commenting on the appointment VR Sports Group CEO Jonny Tungen said;

“ At VR Sports Group we are proud to partner with both Sir Kenny Dalglish MBE and VST Enterprises. Sir Kenny is not only revered as a distinguished player and one of the greatest football managers of all time, but also for his charitable work in society and the community. We are delighted to have strengthened our partnership by bringing together Sir Kenny with a leading tech entrepreneur like Louis-James Davis and his team. Together it creates infinite possibilities, leveraging future oriented technology to design a better, safer and more convenient life for sports fans and the public.

VSTE™ is currently using its VCode^® cyber security technology to work with the UNITED NATIONS as part of their SDG Collaboratory (Sustainable Development Goals) program – to provide a wide range of unique identifiers and technology services to 9 Billion people by 2030. It is also using its V-Health Passport™ across a number of sectors including the airline and aviation industry – with its FIT TO FLY campaign, as well as other major transport infrastructure including rail and maritime assets.

For more information on VCode^® and VPlatform^® technology please visit

https://
www.vstenterprises.com

For more information on V-HEALTH PASSPORT™.
https://www.v-healthpassport.co.uk

For all media enquiries
Please contact Gerard Franklin – Head Of Communications & External Relations
M: 07885 388398  e: [email protected]
VST Enterprises Ltd | The Lexicon | Mount Street | Manchester | M2 5NT

NOTES TO EDITORS

Sir Kenny Dalglish MBE undertook the Orient Gene/ Healgen Covid 19 testing using the rapid ‘antigen’ and rapid ‘antibody’ test cassettes. The test was administered by CHB Medical.

The ten minute Orient Gene/ Healgen antibody test has been validated by multiple organisations and bodies including Imperial College London details of which can be provided on request. It is manufactured in an FDA approved facility and CE marked. The 15 minute Orient Gene/Healgen antigen test kit has been Public Health England assessed and passed and is manufactured in an FDA approved facility and CE marked.

Antigen Test Cassette – Relative Sensitivity: 97% Relative Specificity: 99% Accuracy: 99%

Antibody Test Cassette – Relative Sensitivity: 100% Relative Specificity: 100% Accuracy: 100%

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/cffeb53b-cbb9-4208-9595-27b5e6508e81
https://www.globenewswire.com/NewsRoom/AttachmentNg/9e501635-2fdc-41e6-9825-ee379ba3a15f
https://www.globenewswire.com/NewsRoom/AttachmentNg/64d2bb4c-1214-420a-8c46-5c695742ac66